Cd 10 neg, bcl-2 negative, cd1d positive for FL. What tests might relevant or what's it make you think about my FL...

Understanding Your Follicular Lymphoma Immunophenotype

Thank you for sharing your test results. Let me help you understand what these specific markers mean for your FL diagnosis.

What Your Immunophenotype Shows

Your results show an unusual pattern for follicular lymphoma:

CD10 negative, BCL-2 negative, CD1D positive

According to the NCCN Guidelines for Patients: Follicular Lymphoma, the typical immunophenotype (the pattern of protein markers) for FL is usually:

• CD10+ (positive)
• BCL2+ (positive)
• CD23+/- (may or may not be present)
• CD20+ (positive)
• BCL6+ (positive)

The guidelines specifically note: "Rare cases of FL may be CD10- or BCL2-." Your results fit into this rare category.

What [facility removed]ally

Your negative CD10 and BCL-2 markers are atypical for standard FL, which is why your care team likely did additional testing to confirm the diagnosis. The CD1D positive finding is also noteworthy and suggests your pathologist was carefully characterizing your specific lymphoma subtype.

Why This Matters for Your Care

According to NCCN Guidelines, when immunophenotyping shows unusual patterns, doctors use specialized techniques like flow cytometry (which measures cell characteristics using light and dyes) or immunohistochemistry (which uses antibodies to identify specific markers) to distinguish FL from other types of non-Hodgkin lymphoma, such as diffuse large B-cell lymphoma (DLBCL).

Questions to Ask Your Oncologist

Since your immunophenotype is atypical, these questions will help you understand your specific situation:

1. "Given my unusual CD10 and BCL-2 negative pattern, how confident are you in the FL diagnosis, and what other tests confirmed this?"

2. "What does the CD1D positive finding tell you about my lymphoma, and does it affect treatment recommendations?"

3. "Are there any other rare FL subtypes I should know about, and does my pattern change how you'll monitor my disease?"

4. "Will my immunophenotype be rechecked during or after treatment, since the guidelines mention immunophenotype can change as cancer progresses?"

5. "Should I have any additional molecular testing (like gene rearrangement studies) given my atypical markers?"

Next Steps

The NCCN Guidelines emphasize that pathologists use immunophenotyping to distinguish FL from other lymphomas, and your unusual pattern likely prompted careful analysis. Your oncologist should be able to explain exactly why they're confident in the FL diagnosis despite these atypical markers, and whether this affects your treatment plan.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.